Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 16Colorectal Neoplasms 7Small Cell Lung Carcinoma 4Neoplasm Metastasis 4Stomach Neoplasms 3Recurrence 3Biliary Tract Neoplasms 3Sarcoma, Ewing 2Rhabdomyosarcoma 2Ovarian Neoplasms 2Nasopharyngeal Carcinoma 2Fallopian Tube Neoplasms 2Cholangiocarcinoma 2Triple Negative Breast Neoplasms 1Somatostatinoma 1Solid Tumor 1Small Cell Lung Cancer Extensive Stage 1Small Bowel Adenocarcinoma 1Rectal Neoplasms 1Rectal Cancer Patients 1Pancreatic Ductal Adenocarcinoma 1Pancreatic Cancer Non-resectable 1Pancreatic Cancer Metastatic to Liver 1Pancreatic Adenocarcinoma 1PDAC - Pancreatic Ductal Adenocarcinoma 1Osteosarcoma 1Neoplasms 1Neoadjuvant Chemotherapy 1Metastatic Pancreatic Adenocarcinoma 1Locally Advanced Rectal Cancer (LARC) 1

Interventions

Oxaliplatin 2130-nm albumin-bound paclitaxel 2irinotecan sucrosofate 1folfirinox 1camrelizumab 1Surgical Procedures, Operative 1S 1 (combination) 1Leucovorin 1Gemcitabine 1Fluorouracil 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Borderline Resectable Pancreatic Cancer × irinotecan sucrosofate × Clear all
NCT06345300 2024-04-03

NALIRIFOX in Combination With Camrelizumab for BRPC: a Prospective, Exploratory Study

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2 Unknown
40 enrolled
Gastrointestinal

Borderline Resectable Pancreatic Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡